Eugia Pharma receives USFDA Approval for Argatroban in Sodium Chloride Injection

Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Argatroban in Sodium Chloride Injection 50 mg/50 mL .

Indications for this product include Prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia; Anticoagulant in adult patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.

Refer to package insert for full prescribing information.